| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | TGX221 | GDSC1000 | pan-cancer | AAC | -0.07 | 0.1 |
| mRNA | AS601245 | GDSC1000 | pan-cancer | AAC | -0.052 | 0.1 |
| mRNA | FTI-277 | GDSC1000 | pan-cancer | AAC | -0.051 | 0.1 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.056 | 0.1 |
| mRNA | AZD0530 | CCLE | pan-cancer | AAC | -0.071 | 0.1 |
| mRNA | GSK-1904529A | GDSC1000 | pan-cancer | AAC | -0.05 | 0.1 |
| mRNA | THZ-2-102-1 | GDSC1000 | pan-cancer | AAC | -0.045 | 0.1 |
| mRNA | TW 37 | GDSC1000 | pan-cancer | AAC | -0.049 | 0.1 |
| mRNA | TPCA-1 | CTRPv2 | pan-cancer | AAC | 0.049 | 0.1 |
| mRNA | PF-4800567 hydrochloride | CTRPv2 | pan-cancer | AAC | 0.083 | 0.1 |